why choose us

First received: December 05, 2022

Clinical Trial: Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

Study Status: Completed

Recruit Status: RECRUITING

Condition: Schizophrenia

Study Type: INTERVENTIONAL


Official Title: Open-label Safety Study of a 1-year 8 to 24 mg/Day Dose Regimen of Iloperidone (FANAPT®) in Adolescent Patients With Schizophrenia or Bipolar I Disorder

Brief Summary: To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.

Read more